Alfred L. Garfall, MD, MS

faculty photo
Assistant Professor of Medicine at the Hospital of the University of Pennsylvania
Department: Medicine

Contact information
Division of Hematology Oncology
Perelman Center for Advanced Medicine
12th Floor, South Pavilion
Office #12-173
3400 Civic Center Blvd.
Philadelphia, PA 19104
Office: 215-662-7910
Fax: 215-615-5888
Education:
AB (Molecular Biology)
Princeton University, 2002.
MD
New York University School of Medicine, 2008.
MS (Translational Research)
University of Pennsylvania, 2014.
Permanent link
 
> Perelman School of Medicine   > Faculty   > Details

Description of Clinical Expertise

Multiple Myeloma, Lymphoma, Bone Marrow Transplantation

Description of Research Expertise

Clinical Trials, Immunotherapy, Translational Research

Selected Publications

Bange EM, Han NA, Wileyto P, Kim JY, Gouma S, Robinson J, Greenplate AR, Hwee MA, Porterfield F, Owoyemi O, Naik K, Zheng C, Galantino M, Weisman AR, Ittner CAG, Kugler EM, Baxter AE, Oniyide O, Agyekum RS, Dunn TG, Jones TK, Giannini HM, Weirick ME, McAllister CM, Babady NE, Kumar A, Widman AJ, DeWolf S, Boutemine SR, Roberts C, Budzik KR, Tollett S, Wright C, Perloff T, Sun L, Mathew D, Giles JR, Oldridge DA, Wu JE, Alanio C, Adamski S, Garfall AL, Vella LA, Kerr SJ, Cohen JV, Oyer RA, Massa R, Maillard IP, Maxwell KN, Reilly JP, Maslak PG, Vonderheide RH, Wolchok JD, Hensley SE, Wherry EJ, Meyer NJ, DeMichele AM, Vardhana SA, Mamtani R, Huang AC.: CD8(+) T cells contribute to survival in patients with COVID-19 and hematologic cancer. Nat Med Online ahead of print, May 2021.

Garfall A, Dancy E, Cohen A, Wang WH, Frai J, Suhoski M,Levine B, Siegel D, Stadtmauer E, Vogl D, Waxman A, Rapoport A, Milone M, June C, Melehorst J: T cell phenotypes associated with effective CAR T cell therapy in post-induction versus relapsed multiple myeloma. Blood Adv 3(19): 2812-2815, Oct 2019

Garfall AL, Stadtmauer EA, Hwang WT, Lacey SF, Melenhorst JJ, Krevvata M, Carroll MP, Matsui WH, Wang Q, Dhodapkar MV, Dhodapkar K, Das R, Vogl DT, Weiss BM, Cohen AD, Mangan PA, Ayers EC, Nunez-Cruz S, Kulikovskaya I, Davis MM, Lamontagne A, Dengel K, Kerr NDS, Young RM, Siegel DL, Levine BL, Milone MC, Maus MV, June CH: Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. JCI Insight 4(4): e127684, Feb 2019.

Cohen AD, Garfall AL, Dogan A, Lacey SF, Martin C, Lendvai N, Vogl DT, Spear M, Lesokhin AM: Serial treatment of relapsed/refractory multiple myeloma with different BCMA-targeting therapies. Blood Adv 3(16): 2487-2490, Aug 2019.

Cornell RF, Ky B, Weiss BM, Dahm CN, Gupta DK, Du L, Carver JR, Cohen AD, Engelhardt BG, Garfall AL, Goodman SA, Harrell SL, Kassim AA, Jadhav T, Jagasia M, Moslehi J, O'Quinn R, Savona MR, Slosky D, Smith A, Stadtmauer EA, Vogl DT, Waxman A, Lenihan D.: Prospective Study of Cardiac Evens During Proteasome Inhibitor Therapy for Relapsed Multiple Myeloma. J Clin Oncol. 37(22): 1946-1955, Jun 2019.

Cohen AD, Garfall AL, Stadtmauer EA, Melenhorst JJ, Lacey SF, Lancaster E, Vogl DT, Weiss BM, Dengel K, Nelson A, Plesa G, Chen F, Davis MM, Hwang WT, Young RM, Brogdon JL, Isaacs R, Pruteanu-Malinici I, Siegel DL, Levine BL, June CH, Milone MC: B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. J Clin Invest 129(6): 2210-2221, Mar 2019.

Waxman Adam J, Clasen Suparna, Hwang Wei-Ting, Garfall Alfred, Vogl Dan T, Carver Joseph, O'Quinn Rupal, Cohen Adam D, Stadtmauer Edward A, Ky Bonnie, Weiss Brendan M: Carfilzomib-Associated Cardiovascular Adverse Events: A Systematic Review and Meta-analysis. JAMA Oncol 4(3): e174519, Mar 2018.

Rapoport AP, Stadtmauer EA, Binder-Scholl GK, Goloubeva O, Vogl DT, Lacey SF, Badros AZ, Garfall A, Weiss B, Finklestein J, Kulikovskaya I, Sinha SK, Kronsberg S, Gupta M, Bond S, Melchiori L, Brewer JE, Bennett AD, Gerry AB, Pumphrey NJ, Williams D, Tayton-Martin HK, Ribeiro L, Holdich T, Yanovich S, Hardy N, Yared J, Kerr N, Philip S, Westphal S, Siegel DL, Levine BL, Jakobsen BK, Kalos M, June CH.: NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. Nature Medicine 21(8): 914, Aug 2015.

Garfall AL, Maus MV, Hwang WT, Lacey SF, Mahnke YD, Melenhorst JJ, Zheng Z, Vogl DT, Cohen AD, Weiss BM, Dengel K, Kerr N D S, Bagg A, Levine BL, June CH, Stadtmauer EA: Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma. The New England Journal of Medicine 373(11): 1040-7, Sep 2015.

Huntington Scott F, Weiss Brendan M, Vogl Dan T, Cohen Adam D, Garfall Alfred L, Mangan Patricia A, Doshi Jalpa A, Stadtmauer Edward A: Financial toxicity in insured patients with multiple myeloma: a cross-sectional pilot study. The Lancet. Haematology 2(10): e408-16, Oct 2015.

back to top
Last updated: 09/20/2021
The Trustees of the University of Pennsylvania